Call For Manuscripts! Stem Cells International

Stem Cells International

Call For Papers – Full Announcement

In the past decades, stem cell is always the research hotfspot in the field of neuroscience because of its important role for regeneration medicine. Stem cells could aid neurogenesis and functional recovery in animals and human beings after brain injury, for example, stroke or traumatic brain injury (TBI). Neural stem cells (NSCs) replacement is considered as a very promising therapy strategy for brain injury. Many studies had been conducted in animal experiments and clinical trials.

The journal of “Stem Cells International” is going to publish a special issue of brain injury and stem cells
replacement. Any manuscripts regarding brain injury (stroke or TBI) and using stem cells (NSCs or other stem cells) to achieve neurogenesis and repair the neural function are welcomed for submission.Moreover, papers using magnetic resonance imaging (MRI) methods for tracking these stem cells are also encouraged for submission.

Potential topics include but are not limited to the following:

  • Recent basic researches on TBI, for example its mechanism
  • Stem cells replacement studies on the treatment of TBI in animals or preclinical trials, especially neural stem cells
  • In vivo MRI tracking of stem cells in animal brain after cellular replacement

Authors can submit their manuscripts through the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/sci/bisr/.

Announcement for 2017 Experimental Biology

The annual Experimental Biology meeting will take place April 22-26, 2017 in Chicago, IL. This multidisciplinary, scientific meeting features plenary and award lectures, workshops, oral and posters presentations, on-site career services and exhibits spotlighting equipment, supplies and publications required for research labs and experimental study.

Bonnie Blazer-Yost, PhD, will be chairing and speaking at a symposium titled Transport Proteins and Cellular Signaling in Choroid Plexus Epithelia. Elucidating the regulation of transport proteins in the choroid plexus is important for understanding normal brain development and function, but is also crucial for resolving a variety of cerebral challenges that lead to brain edema as well as developing treatment for diseases such as pediatric hydrocephalus, normal pressure adult hydrocephalus, sleep disorders, and age-related dementia. Recent progress in the field warrants a symposium on transporters and signaling in the choroid plexus epithelia. The symposium is expected to attract scientists from the broader fields of blood-brain-barriers, transport physiology as well as water and solute homeostasis. One of the major goals of the symposia is to stimulate cross-disciplinary discussion regarding the regulation of CSF quantity and quality in both health and disease.

Dr. Blazer-Yost is a HANDS member and a recipient of HA’s 2015 innovator award.

Click here for more information on the 2017 Experimental Biology Conference.

SRHSB Annual Meeting

From June 21 to 24, 2017, the Society for Research into Hydrocephalus and Spina Bifida (SRHSB) Annual Meeting will take place. SRHSB is a 61-year old Society that is unique in combining research and clinical interests in both hydrocephalus and spina bifida. The conference will take place in St. Louis, MO at the Eric P. Newman Educational Center on the WUSM campus. Young investigators are also invited to apply for the Guthkelch Award, which will give $2,300 to the best presentation.

Abstracts and Guthkelch Award submissions are due February 15, 2017.
This year, SRHSB will join with the International Children’s Continence Society (ICCS), led by Paul Austin, a pediatric urologist at WUSM, for a comprehensive conference of about 300 professionals. The ICCS is a very active group with an international membership 2-3 times the size of the SRHSB.  Because the ICCS shares the SRHSB’s interest in spina bifida, there will be a full day for combined presentations by members of both Societies. There will also be a Special Symposium on Transition of Care in Hydrocephalus and Spina Bifida and several excellent invited presentations on fetal treatments for myelomeningocele and tethered cord.

For more information, go to the SRHSB website.

Device Currently in Clinical Trials May Delay the Need for Emergency Shunt Surgery

Alcyone Lifesciences IncOn August 2, 2016, Alcyone Lifesciences, Inc., a medical device company focused on the development of treatment devices for hydrocephalus and other neurological conditions, announced the clinical use of its ReFlowTM System in a study at Boston Children’s Hospital (BCH).

What is this device and what is it designed to do?

The purpose of the ReFlowTM System is to reduce emergency risks associated with a blocked ventricular catheter.  The ReFlowTM system is composed of an in-line flusher reservoir and proprietary ventricular catheter and is compatible with commercially available flow regulating valves and accessories. The flusher is designed to non-invasively discharge fluid towards the ventricular catheter thereby dislodging choroid plexus that may be obstructing cerebrospinal fluid (CSF) flow through the shunt system. The catheter design is unique in that it includes an ‘emergency release.’ If the flusher is unable to unblock the standard catheter holes, the pressure from the fluid injection will open an additional hole in the catheter to re-establish flow.

Currently, investigators at BCH are testing the flusher in patients already scheduled for a shunt revision. The ultimate goal, however, is to clinically implement the fully implantable system, which is a noninvasive way to reestablish fluid flow and prevent the need for an immediate emergency shunt revision. This means that the ReFlowTM System would be implanted during an initial shunt surgery. If the patient began to have symptoms consistent with a shunt obstruction, the flusher would be activated, non-invasively, by a qualified healthcare professional.

As reported by PR Newswire, Dr. Joseph Madsen, neurosurgeon, co-inventor and pre-clinical investigator, said, “It is encouraging that the ReFlowTM System works in the operating room just as it does in bench top and animal studies. This pilot study is set to collect pressure and flow rate measurements in order to determine the safety of ’flushing‘ an existing ventricular shunt catheter.”

Dr. Benjamin Warf, the principal investigator, stated, “This is a simple and intuitive idea, and I am very hopeful that it will benefit many children by reducing shunt problems.”

Clinical Trial and FDA Submission

The official title of the study is Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters, with Dr. Benjamin Warf, Dr. Joseph Madsen and Dr. Tomer Anor from BCH as the investigators. The objective of this pilot study is to collect flow rate measurements in order to determine the safe “flushing” of a ventricular shunt catheter. A premeasured amount of saline injection volumes are being used to flush the shunt catheter using the ReFlowTM in-line Flusher. Pressure recordings of the injected fluid are recorded and monitored throughout the study. Based on the study’s objective and characteristics, the Food and Drug Administration (FDA) classifies this study as a Phase 3 trial. Phase 3 trials gather information about safety and effectiveness by studying different populations and dosages.

Alcyone has now filed a 510 (k) Premarket Notification to the FDA for commercial approval of the ReFlowTM System. If approved, the investigators could begin studying the effectiveness of the fully implantable the ReFlowTM System in hydrocephalus patients.

For more information on the on-going BCH clinical study, please visit ClinicalTrials.gov and search for NCT 02651337.

News Stories on the ReFlowTM System

Alcyone Lifesciences Announces Clinical Use of the ReFlow™ System for the Treatment of Hydrocephalus

Alcyone Lifesciences, Inc. Announces Allowance of First Patent Related to ReFlow™ System for the Treatment of Hydrocephalus

Alcyone Lifesciences, Inc.: Private Company Information – Businessweek

 

Welcome to the HA Network for Discovery Science (HANDS)

Welcome to hydrocephalus researchers!  Based on resounding feedback from basic scientists at the two most recent NIH hydrocephalus research workshops, the Hydrocephalus Association is establishing the Hydrocephalus Association Network for Discovery Science (HANDS).  HANDS will provide a virtual and physical places for basic scientists to connect and collaborate on novel research hypotheses of interest to the hydrocephalus community.  HA will provide collaboration infrastructure and support for meetings of working groups within the network.  The goal will be to work together to apply for NIH funding for breakthrough scientific ideas to advance the field for hydrocephalus.  Go to our membership page to sign up.

Annual Meeting Announcement for SRHSB

Annual Meeting of the Society for Research into Hydrocephalus and Spina Bifida

Stirling, Scotland
June 29-July 2
https://www.srhsb.com/conferences/stirling-2016

The annual SRHSB meeting will be held on June 29-July 2, 2016 in Stirling, Scotland. Andy Wynd and his local organizing committee are putting together a wonderful scientific and social programme.

The SRHSB is focused on increasing public awareness of hydrocephalus and spina bifida and to promote research across the diverse fields of study relevant to these conditions, with the ultimate goal of alleviating, managing and preventing the conditions. The research interests of SRHSB have a broad range from fetal imaging, termination of pregnancy and neonatology, to normal pressure  hydrocephalus  in the older population.

SRHSB website: https://www.srhsb.com/conferences/stirling-2016

  • First week of January, 2016
    • Abstract submission open
    • Norman and Margaret Guthkelch Award submission open
    • 2016 Casey Holter Essay Prize submission open
  •  Registration details
    • Abstract submission deadline: February 26, 2016
    • Norman and Margaret Guthkelch Award application deadline:February 26, 2016
    • 2016 Casey Holter Essay Prize application deadline:February 26, 2016
    • Abstracts and Guthkelch applications reviewed at the Executive Committee meeting:March 12, 2016
    • Presentation and Guthkelch finalists notified:March 15, 2016
    • Discounted early pre-registration and accommodation deadline:May 15, 2016
    • Non-discounted pre-registration deadline: June 15, 2016

New Hydrocephalus Association Grant Opportunity

Hydrocephalus Association Grants

2015 Grants


Innovator Awards: Hydrocephalus Therapeutics Research

This opportunity has passed.

The Hydrocephalus Association is soliciting applications from investigators for Innovator Awards to be used for understanding disease mechanisms and the identification and pre-clinical testing of therapies to prevent or reverse all forms of hydrocephalus. The goal of this initiative is to provide seed funding for bold and innovative research with the potential to transform the field of hydrocephalus through the understanding of disease mechanisms and the development of novel therapies.

Click Here for the full RFA and Application Details